Custirsen as Treatment for Prostate Cancer
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.
Clinical Pearls:
- A phase III trial of custirsen in combination with docetaxel has been conducted and results are expected to be available within a year
- Based on a phase II trial, the combination appeared to be more effective than docetaxel when used as mono therapy
- This phase III trial will determine if custirsen plus docetaxel is more effective than docetaxel alone for patients with castration-resistant prostate cancer
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More
